Skip to main
ODTX

ODTX Stock Forecast & Price Target

ODTX Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Odyssey Therapeutics is a strong contender with a diverse and promising pipeline of treatments for inflammatory and immune diseases including OD-001 for IBD. With a target availability in the US and EU by 2030-2031, OD-001 has low risk of side effects and potential for fast and effective treatment. The collaboration with Terray on a new treatment adds to the company's potential for growth and success in the market.

Bears say

Odyssey Therapeutics is facing a negative outlook due to several factors. Firstly, their lead asset, OD-001, has a competitive market with multiple other drugs targeting the same indications, making it difficult for them to stand out. Additionally, their pipeline is still in early stages of development and it will be several years before they have a potential candidate in the market. Furthermore, the company's financials show a decrease in revenue and an increase in expenses, which may impact their ability to fund their research and development efforts in the future.

ODTX has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Odyssey Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Odyssey Therapeutics Inc (ODTX) Forecast

Analysts have given ODTX a Buy based on their latest research and market trends.

According to 4 analysts, ODTX has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Odyssey Therapeutics Inc (ODTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.